Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics Limited has successfully completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan. The funds raised will be used to support drug manufacturing, clinical trials, and working capital, extending the company’s funding runway into 2027. The placement was strongly supported by both new and existing investors, including Lantheus Holdings, which increased its shareholding to 14.5%. This financial boost is expected to advance Radiopharm’s six clinical programs and strengthen its position in the radiopharmaceutical industry.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a company that develops a platform of radiopharmaceutical products for diagnostic and therapeutic uses. The company focuses on creating innovative solutions in the field of radiopharmaceuticals.
Average Trading Volume: 4,552,171
Technical Sentiment Signal: Buy
Current Market Cap: A$87.5M
Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.